Detail akcie Selvita online

Business Summary: Ryvu Therapeutics SA is a Poland-based company that operates in the biotechnology industry. The Company focuses on oncology drug discovery and research and development (R&D) activities. Its primary products are therapeutic drug candidates and related research programs for cancer treatment. These products are biotechnology based therapies and drug development assets that are evaluated and advanced through preclinical and clinical research. The primary goal of this technology is to identify therapeutic targets and support the development of medicines for patients with cancer. The Company also conducts contract research activities and enters licensing and research collaboration agreements related to biotechnology and drug development.
Financial Summary: BRIEF: For the six months ended 30 June 2026, Ryvu Therapeutics SA revenues decreased 1% to PLN28.9M. Net loss decreased 56% to PLN25.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Innovative segment loss decrease of 56% to PLN28.8M. Basic Earnings per Share excluding Extraordinary Items increased from -PLN2.54904 to -PLN1.11176.